AbbVie vs Abbott Laboratories
ABBV and ABT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ABBV and ABT compare
AbbVie is the larger company, worth 2.8 times as much as Abbott Laboratories ($521B against $188B).
On earnings, Abbott Laboratories is cheaper: it trades at 40.2× trailing earnings, against 83.3× for AbbVie.
AbbVie grew revenue faster over the last twelve months (10.4% versus 10.0% for Abbott Laboratories).
AbbVie keeps more of each dollar of sales as profit, with a net margin of 9.8% compared with 9.7% at Abbott Laboratories.
Both pay dividends: AbbVie yields 2.3% and Abbott Laboratories 2.3%.
Abbott Laboratories scores higher on the StockData Score (12 against 10 for AbbVie), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ABBV | ABT |
|---|---|---|
| Size and price | ||
| Market cap | $521B | $188B |
| Share price | $295.03 | $108.52 |
| Change, 1 year | 26.5% | −15.8% |
| Change, 5 years | 154% | −14.4% |
| Beta (5Y) | 0.28 | 0.45 |
| Employees | 57K | 115K |
| StockData Score | ||
| Total score | 10 | 12 (better) |
| Valuation score | 0 | 0 |
| Growth score | 3 | 3 |
| Performance score | 2 | 3 (better) |
| Health score | 2 | 4 (better) |
| Dividend score | 3 (better) | 2 |
| Valuation | ||
| P/E | 83.3× | 40.2× (better) |
| P/S | 8.1× | 3.9× (better) |
| P/B | – | 3.7× |
| EV/EBITDA | 34.7× | 32.4× (better) |
| P/FCF | 28.6× | 27.8× (better) |
| FCF yield | 3.5% | 3.6% (better) |
| Fair value | $157.48 | $72.76 |
| Margin of safety | −87.3% | −49.1% (better) |
| Growth | ||
| Revenue growth (TTM) | 10.4% (better) | 10.0% |
| Revenue growth, 5Y average | 6.0% (better) | 5.1% |
| Net income growth (TTM) | 67.7% (better) | −66.4% |
| EPS growth (TTM) | 68.6% (better) | −66.2% |
| EPS growth, 5Y average | −2.8% | 8.3% (better) |
| Profitability | ||
| Gross margin | 71.5% (better) | 56.9% |
| Operating margin | 26.2% (better) | 13.8% |
| Net margin | 9.8% (better) | 9.7% |
| FCF margin | 28.3% (better) | 14.0% |
| Return on equity | – | 9.2% |
| Return on invested capital | 20.1% (better) | 7.1% |
| Financial health | ||
| Debt / equity | – | 0.61 |
| Net debt / EBITDA | 3.81 (better) | 4.04 |
| Interest coverage | 5.8× | 6.7× (better) |
| Current ratio | 0.81 | 1.45 (better) |
| Altman Z-score | 2.86 | 3.36 (better) |
| Piotroski F-score | 8 (better) | 6 |
| Dividends and buybacks | ||
| Dividend yield | 2.3% (better) | 2.3% |
| Payout ratio | 190% | 92.0% |
| Years of dividend growth | 11 (better) | 3 |
| Dividend growth, 5Y average | 6.6% | – |
| Buyback yield | 0.29% | 0.82% (better) |
| Shareholder yield | 2.6% | 3.1% (better) |
| Ownership | ||
| Held by institutions | 75.6% | 79.8% |
| Held by insiders | 0.09% | 0.50% |
| Insider net buying, 12 months | −$30.8M (better) | −$43.3M |
| Superinvestors holding | 3 (better) | 2 |
| Short interest, % of float | 0.90% | 1.1% |
Go deeper
- ABBV stock overview
- ABBV income statement
- ABBV valuation and score
- ABT stock overview
- ABT income statement
- ABT valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.